Enhanced ocular bioavailability of fluconazole from niosomal gels and microemulsions: formulation, optimization and in vitro-in vivo evaluation.

Fungal keratitis may cause vision loss if it is not treated. Methods other than ocular delivery exhibited several limitations. No previous studies investigated and compared ocular bioavailability of fluconazole (FLZ) from niosomal gels and microemulsions. Niosomal gels of FLZ (0.3% w/w) based on Span((R)) 60 and cholesterol (CH) using 1% w/w carbopol((R)) 934 (CP) were evaluated. FLZ microemulsions (0.3% w/v) containing isopropyl myristate (IPM, as oil phase) and a 3:1 mixture of Tween((R)) 80 (as surfactant) and polyethylene glycol 400 (PEG 400, as cosurfactant) were characterized. Optimized formulations were compared for their ocular bioavailability in rabbit's. Nanoscopic niosomes (63.67-117.13 nm) and microemulsions (57.05-59.93 nm) showed respective negative zeta potential ranges of -45.37 to -61.40 and -20.50 to -31.90 mV and sustained release up to 12 h. Entrapment efficiency (EE%) of niosomes ranged from 56.48% to 70.67%. Niosomal gels were more sustainable than niosomes and microemulsions. The most stable niosomal gel based on Span((R)) 60 and CH at a molar ratio of 5:5 and microemulsion containing 45% w/w IPM and 40% w/w of 3:1 Tween((R)) 80-PEG 400 mixture significantly (p < 0.0001) enhanced FLZ ocular bioavailability compared with its solution. Niosomal gel showed higher bioavailability than microemulsion by approximate to 2-fold.